Challenges and future directions for the use of GLP-1 receptor agonists in children and adolescents living with obesity
Obesity and Endocrinology · 06.01.2026 · 2 (1)
DOI: 10.1093/obendo/wjag009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Obesity and Endocrinology, online erschienen am 03.06.2026. Verfasst von Giulio Equitani und 1 weiteren Autor:innen. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Objective
To critically discuss evidence from randomized clinical trials investigating efficacy of glucagon-like peptide 1 receptor agonists in paediatric population and highlight important gap in knowledge while anticipating planned sponsored and investigator-initiated study.
Methods
Expert's non-systematic revision of the literature and opinion. Results and conclusion Intensive health behaviour and lifestyle treatment remains the foundation of care; however, obesity management medications, that is, glucagon-like peptide-1 receptor agonists, are increasingly integrated into management strategies for selected youth with moderate to severe obesity. While reductions in body mass index z-score have been found as clinically meaningful thresholds associated with cardiometabolic improvement, efficacy assessment must extend beyond weight-centric metrics to include amelioration of comorbidities, mental health outcomes, quality of life, and social functioning. Current limitations include short trial duration, heterogeneity in outcomes, absence of head-to-head comparisons, and limited long-term safety data, particularly regarding growth, pubertal progression, bone health, and neurocognitive development. Ongoing sponsored and investigator-initiated studies are expected to fill important gap in knowledge informing safety in younger children, and exploring differential responses in specific phenotypes, including youth with polycystic ovary syndrome or metabolic-associated steatotic liver disease. Adherence and long-term engagement are critical challenges in adolescent populations, underscoring the need for patient-centred care, shared decision-making, and structured frameworks such as the Ask, Assess, Advise, Agree, Assist approach. Robust paediatric-specific evidence is required to guide prioritization, treatment algorithms, and personalization of obesity management medication therapy. A balanced, holistic, and evidence-based approach is required to optimize outcomes and reduce lifelong obesity-related morbidity.
Zitieren
APA
Equitani, G., & Manco, M. (2026). Challenges and future directions for the use of GLP-1 receptor agonists in children and adolescents living with obesity. Obesity and Endocrinology, 2(1). https://doi.org/10.1093/obendo/wjag009
Vancouver
Equitani G, Manco M. Challenges and future directions for the use of GLP-1 receptor agonists in children and adolescents living with obesity. Obesity and Endocrinology. 2026;2(1). doi:10.1093/obendo/wjag009
BibTeX
@article{Equitani2026,
author = {Equitani, Giulio and Manco, Melania},
title = {Challenges and future directions for the use of GLP-1 receptor agonists in children and adolescents living with obesity},
journal = {Obesity and Endocrinology},
year = {2026},
volume = {2},
number = {1},
doi = {10.1093/obendo/wjag009}
}
EUVIMED